Literature DB >> 8962129

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.

F Yuan1, Y Chen, M Dellian, N Safabakhsh, N Ferrara, R K Jain.   

Abstract

The hyperpermeability of tumor vessels to macromolecules, compared with normal vessels, is presumably due to vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) released by neoplastic and/or host cells. In addition, VEGF/VPF is a potent angiogenic factor. Removal of this growth factor may reduce the permeability and inhibit tumor angiogenesis. To test these hypotheses, we transplanted a human glioblastoma (U87), a human colon adenocarcinoma (LS174T), and a human melanoma (P-MEL) into two locations in immunodeficient mice: the cranial window and the dorsal skinfold chamber. The mice bearing vascularized tumors were treated with a bolus (0.2 ml) of either a neutralizing antibody (A4.6.1) (492 micrograms/ml) against VEGF/VPF or PBS (control). We found that tumor vascular permeability to albumin in antibody-treated groups was lower than in the matched controls and that the effect of the antibody was time-dependent and influenced by the mode of injection. Tumor vascular permeability did not respond to i.p. injection of the antibody until 4 days posttreatment. However, the permeability was reduced within 6 h after i.v. injection of the same amount of antibody. In addition to the reduction in vascular permeability, the tumor vessels became smaller in diameter and less tortuous after antibody injections and eventually disappeared from the surface after four consecutive treatments in U87 tumors. These results demonstrate that tumor vascular permeability can be reduced by neutralization of endogenous VEGF/ VPF and suggest that angiogenesis and the maintenance of integrity of tumor vessels require the presence of VEGF/VPF in the tissue microenvironment. The latter finding reveals a new mechanism of tumor vessel regression-i.e., blocking the interactions between VEFG/VPF and endothelial cells or inhibiting VEGF/VPF synthesis in solid tumors causes dramatic reduction in vessel diameter, which may block the passage of blood elements and thus lead to vascular regression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962129      PMCID: PMC26210          DOI: 10.1073/pnas.93.25.14765

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Microvascular permeability of normal and neoplastic tissues.

Authors:  L E Gerlowski; R K Jain
Journal:  Microvasc Res       Date:  1986-05       Impact factor: 3.514

Review 2.  Transport of molecules across tumor vasculature.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  Leukocyte-endothelial adhesion and angiogenesis in tumors.

Authors:  R K Jain; G C Koenig; M Dellian; D Fukumura; L L Munn; R J Melder
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

Authors:  K J Kim; B Li; K Houck; J Winer; N Ferrara
Journal:  Growth Factors       Date:  1992       Impact factor: 2.511

5.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice.

Authors:  M Leunig; F Yuan; M D Menger; Y Boucher; A E Goetz; K Messmer; R K Jain
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

6.  Radiation sensitivity of cultured human glioblastoma cells.

Authors:  L E Gerweck; P L Kornblith; P Burlett; J Wang; S Sweigert
Journal:  Radiology       Date:  1977-10       Impact factor: 11.105

Review 7.  Determinants of tumor blood flow: a review.

Authors:  R K Jain
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

8.  Tumor-secreted vascular permeability factor/vascular endothelial growth factor influences photosensitizer uptake.

Authors:  W G Roberts; T Hasan
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

9.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

10.  A novel endothelial-specific membrane protein is a marker of cell-cell contacts.

Authors:  M G Lampugnani; M Resnati; M Raiteri; R Pigott; A Pisacane; G Houen; L P Ruco; E Dejana
Journal:  J Cell Biol       Date:  1992-09       Impact factor: 10.539

View more
  207 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

2.  Control of apoptosis during angiogenesis by survivin expression in endothelial cells.

Authors:  D S O'Connor; J S Schechner; C Adida; M Mesri; A L Rothermel; F Li; A K Nath; J S Pober; D C Altieri
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

3.  Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice.

Authors:  A Gilead; M Neeman
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 4.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

Review 5.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.

Authors:  Hemant Sarin
Journal:  Ther Deliv       Date:  2010-08

6.  Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Authors:  Basel Sitohy; Janice A Nagy; Shou-Ching Shih Jaminet; Harold F Dvorak
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 7.  Mathematical modeling of tumor-induced angiogenesis.

Authors:  Nikos V Mantzaris; Steve Webb; Hans G Othmer
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

Review 8.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 9.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

10.  Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.

Authors:  Giordana Bettini; Stella Blandamura; Giorgia Saia; Alberto Bedogni
Journal:  BMJ Case Rep       Date:  2012-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.